REGN vs TRVI
REGN: Regeneron is a leading biotechnology firm that leverages its human genetics research and proprietary technology to discover and commercialize innovative therapies for serious diseases. TRVI: Trevi Therapeutics is a clinical-stage biopharma company developing its lead product candidate, Haduvio, to treat challenging chronic pruritus and chronic cough conditions.
Side-by-side fundamentals
| Metric | REGN | TRVI | Edge |
|---|---|---|---|
| Price as of 2026-10-21 close | $805.67 | $12.77 | |
| Market cap | $82.9B | $1.8B | |
| P/E as of 2026-10-21 | 19.94 | n/a | |
| PEG as of 2026-10-21, 3-year EPS CAGR to FY2025 | 7.21 | n/a | |
| Net margin FY2025, SEC XBRL | +31.4% | n/a | |
| Operating margin FY2025, SEC XBRL | +24.9% | n/a | |
| ROE FY2025, SEC XBRL | +14.4% | -23.3% | REGN higher |
| ROA FY2025, SEC XBRL | +11.1% | -22.1% | REGN higher |
| Debt / equity filed borrowings, leases excl., balance sheet 2026-06-30 | 0.06 | n/a | |
| Revenue growth (YoY) FY2025, SEC XBRL | +1.0% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +5.6% | n/a | |
| Dividend yield as of 2026-09-02 | +0.5% | n/a | |
| Dividend streak (yrs) SEC XBRL | n/a | 0 | |
| Beta as of 2026-09-02 | 0.60 | 0.50 | |
| 1-year return as of 2026-10-21 close | +39.1% | +19.9% | REGN higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.